Overview
Kamada Q3 revenue rises 13% to $47 mln, beating analyst expectations
Adjusted EBITDA for Q3 increases 34% yr/yr, reflecting strong operational performance
Company reiterates full-year 2025 revenue guidance of $178 mln-$182 mln
Outlook
Kamada reiterates 2025 revenue guidance of $178 mln to $182 mln
Company expects 2025 adjusted EBITDA of $40 mln to $44 mln
Kamada to conduct interim futility analysis of InnovAATe trial this quarter
Result Drivers
DIVERSE PORTFOLIO - Revenue growth driven by increased sales of GLASSIA in ex-U.S. markets and VARIZIG in U.S.
SALES MIX - Improved sales mix and increased commercial scale boosted gross margins
PLASMA OPERATIONS - Expansion of plasma collection operations supports revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $47 mln | $45.81 mln (4 Analysts) |
Q3 EPS | $0.09 | ||
Q3 Net Income | $5.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kamada Ltd is $15.00, about 55.6% above its November 7 closing price of $6.66
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 20 three months ago
Press Release: ID:nGNX83lScz
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)